Exchange: NASDAQ·Updated 07:30 PM EST

QQQS News

News
all
press releases
HELP Stock Gaps Higher, Then Fades, On $35 Barclays Target Ahead Of Q4 Psychedelic Drug Trial Results
Barclays’ new price target of $35 implies an upside of about 150% from the stock’s last close on Thursday around $14.
Stocktwits
HELP Stock Gaps Higher, Then Fades, On $35 Barclays Target Ahead Of Q4 Psychedelic Drug Trial Results
Barclays’ new price target of $35 implies an upside of about 150% from the stock’s last close on Thursday around $14.
Stocktwits
More News
TD Cowen lifted its target on HELP to $62 from $8 on Thursday, while maintaining a Buy rating.
Stocktwits
The company noted that if the FDA approves its application, Imosidolimab could address a significant unmet medical need in this rare and life-threatening disorder.
Stocktwits
Kelce will acquire Sleep Number common stock on the open market and receive restricted stock units that vest over the initial three-year term.
Stocktwits
The FDA cited concerns that the controlled phase advance protocols used in studies do not fully replicate real-world jet travel conditions.
Stocktwits
Looking ahead, CEO Gayn Erickson said he expects nearly all of the company’s served markets to experience order growth in the fiscal year, with silicon carbide growth expected to strengthen further in the next fiscal year.
Stocktwits
The private-equity firm has been actively pursuing software deals, with the firm striking a $12.3 billion deal to acquire human resources management software firm Dayforce last week.
Stocktwits
IWM and other small-cap ETFs are gaining steam as earnings growth picks up and investor sentiment starts to shift.
Zacks
IWM gained 4.6% in a month as small caps show signs of life, narrowing the gap with large caps after a long slump. Is this the start of a winning trend or just a short-term rebound?
Zacks
Quarterly revenue fell to $14.1 million from $16.6 million in the fourth quarter of 2024, slightly below the $14.82-million consensus estimate.
Stocktwits

Advertisement|Remove ads.